Gilead Sciences has agreed to acquire an oral IL-23R inhibitor program, led by HCXT-2001, from privately held PepStar ...

Zymeworks entered into a global licensing and collaboration agreement with Roche for ZW209, a trispecific T-cell engager ...

Rising trial amendments drive costly change orders, but AI tools help sponsors spot hidden costs and negotiate better final ...

Racura is pursuing one of cancer’s most elusive targets, pairing a distinctive MYC-inhibition approach with a data-first path ...

Earlier this week, Eli Lilly announced it broke ground on a large site in Houston, Texas. The location will be one of ten US ...

Molecular testing firm Qiagen has agreed to a $52.22-per-share all-cash acquisition by EQT Private Equity.

METiS TechBio has teamed up with Lilly in a deal worth $1.1bn, pairing AI-driven lipid design with pharma expertise to ...

BioXconomy highlights leading Black innovators and leaders in the biotechnology industry.

IQVIA and Veeva extend their partnership, expanding sponsor access to Veeva's clinical trial and data management technology.

Germany’s Merck has agreed to acquire London-based Silence Therapeutics in an all-cash deal, adding a late-stage rare blood ...

The clinical-stage biotech has closed an oversubscribed Series D financing round in a bid to meeting its mission to stop ...

Estuary Biotherapeutics launches with $103 million to take gene therapies for kidney disease into the clinic. The financing ...